254 related articles for article (PubMed ID: 29274707)
1. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
Guan Z; Cheng W; Huang D; Wei A
Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
[TBL] [Abstract][Full Text] [Related]
2. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53.
Calvisi DF; Simile MM; Ladu S; Frau M; Evert M; Tomasi ML; Demartis MI; Daino L; Seddaiu MA; Brozzetti S; Feo F; Pascale RM
Hepatology; 2011 Apr; 53(4):1226-36. PubMed ID: 21480327
[TBL] [Abstract][Full Text] [Related]
3. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
4. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers.
Xin Z; Li Y; Meng L; Dong L; Ren J; Men J
Math Biosci Eng; 2022 Jan; 19(2):1825-1842. PubMed ID: 35135230
[TBL] [Abstract][Full Text] [Related]
6. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
7. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma.
Zhang X; Lv QL; Huang YT; Zhang LH; Zhou HH
J Exp Clin Cancer Res; 2017 Aug; 36(1):105. PubMed ID: 28784180
[TBL] [Abstract][Full Text] [Related]
8. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
9. Aberrant KIF20A expression might independently predict poor overall survival and recurrence-free survival of hepatocellular carcinoma.
Lu M; Huang X; Chen Y; Fu Y; Xu C; Xiang W; Li C; Zhang S; Yu C
IUBMB Life; 2018 Apr; 70(4):328-335. PubMed ID: 29500859
[TBL] [Abstract][Full Text] [Related]
10. A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy.
Fu Q; Yang F; Xiang T; Huai G; Yang X; Wei L; Yang H; Deng S
Sci Rep; 2018 May; 8(1):7933. PubMed ID: 29785036
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
[TBL] [Abstract][Full Text] [Related]
12. MYB proto-oncogene like 2 promotes hepatocellular carcinoma growth and glycolysis via binding to the
Liu M; Du Q; Mao G; Dai N; Zhang F
Bioengineered; 2022 Mar; 13(3):5344-5356. PubMed ID: 35176941
[TBL] [Abstract][Full Text] [Related]
13. A six-gene-based prognostic signature for hepatocellular carcinoma overall survival prediction.
Wang Z; Teng D; Li Y; Hu Z; Liu L; Zheng H
Life Sci; 2018 Jun; 203():83-91. PubMed ID: 29678742
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Fei X; Ma Y; Liu X; Meng Z
Tohoku J Exp Med; 2017 Nov; 243(3):219-226. PubMed ID: 29187705
[TBL] [Abstract][Full Text] [Related]
15. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
16. Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic report.
Lü Y; Zhang J; Li L; Li S; Yang Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 31990034
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma.
He D; Zhang X; Tu J
Cancer Med; 2020 Dec; 9(23):8782-8800. PubMed ID: 32978904
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of long non-coding RNA GAS5-AS1 and its prognostic and diagnostic significance in hepatocellular carcinoma.
Wang Y; Jing W; Ma W; Liang C; Chai H; Tu J
Cancer Biomark; 2018; 22(2):227-236. PubMed ID: 29660898
[TBL] [Abstract][Full Text] [Related]
19. B-MYB-p53-related relevant regulator for the progression of clear cell renal cell carcinoma.
Nientiedt M; Müller K; Nitschke K; Erben P; Steidler A; Porubsky S; Popovic ZV; Waldbillig F; Mühlbauer J; Kriegmair MC
J Cancer Res Clin Oncol; 2021 Jan; 147(1):129-138. PubMed ID: 32951068
[TBL] [Abstract][Full Text] [Related]
20. NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma.
Guo ZY; Zhu ZT
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7238-7251. PubMed ID: 34919223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
